Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
sodium oxybate
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Xyrem
|
| gptkbp:clinicalTrials |
recommended
Phase III cataplexy excessive daytime sleepiness |
| gptkbp:contraindication |
anxiety
depression seizures hallucinations respiratory depression succinic semialdehyde dehydrogenase deficiency |
| gptkbp:controls |
Schedule III
|
| gptkbp:dosageForm |
syrup
|
| gptkbp:drugInterdiction |
true
oral solution central nervous system depressant sodium salt |
| gptkbp:formFactor |
liquid
|
| gptkbp:hasPopulation |
children
adults |
| gptkbp:healthcare |
required
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xyrem
|
| gptkbp:impact |
short-term
long-term |
| gptkbp:interactsWith |
alcohol
antidepressants opioids other CNS depressants |
| gptkbp:label |
black box warning
|
| gptkbp:lastProduced |
2002
|
| gptkbp:manufacturer |
Jazz_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:marketSegment |
available
|
| gptkbp:packaging |
bottle
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchInterest |
ongoing
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
headache nausea confusion insomnia |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
GABA_receptor_agonist
|
| gptkbp:type |
sodium oxybate
|
| gptkbp:usedFor |
narcolepsy
|